Biocartis Issues Q3 Update, Raises €32.7M, Inks US Distribution Deal

Nov 17, 2016

|

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis Group issued an update on its business during the third quarter of fiscal year 2016, and announced €32.7 million ($34.7 million) in private financing and a US distribution deal with Thermo Fisher Scientific for its Idylla diagnostics platform and assays.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biocartis Issues Q3 Update, Raises €32.7M, Inks US Distribution Deal

To read the full story....

Breaking News

AMP Cautions Against Using Cycle Threshold Values for PCR SARS-CoV-2 Tests in Clinical Practice

Prevencio, Atlas Genomics to Commercialize Cardiac Blood Tests

DiaSorin, Qiagen Obtain CE Mark for Lyme Disease Early Detection Test

Sherlock Bio Foundation Licenses CRISPR Tech to Cooper International, United PPE for COVID-19 Tests

FDA Grants EUA to Enzo Biochem Sample Collection Kit for COVID-19 Testing

Qiagen Nabs CE Mark for High-Throughput SARS-CoV-2 Test Kit

Featured White Papers

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

What's Popular?

FDA Issues EUAs for SARS-CoV-2 Tests From Synergy Diagnostic Laboratory, Celltrion

FDA Issues Amendment to Streamline Authorization of Pooled Molecular COVID-19 Testing

Biocartis Files FDA Submission for Microsatellite Instability Test in Colorectal Cancer

UK Researchers Publish Data on qPCR-Based Early-Stage Lyme Disease Test

Qiagen Nabs CE Mark for High-Throughput SARS-CoV-2 Test Kit

Sponsorships